| [1] |
Yin J, Liu G, Zhang Y, et al. Gender differences in gliomas: from epidemiological trends to changes at the hormonal and molecular levels[J]. Cancer Lett, 2024, 598: 217114. DOI: 10.1016/j.canlet.2024.217114.
|
| [2] |
Drexler R, Khatri R, Sauvigny T, et al. A prognostic neural epigenetic signature in high-grade glioma[J]. Nat Med, 2024, 30(6): 1622-1635. DOI: 10.1038/s41591-024-02969-w.
pmid: 38760585
|
| [3] |
国家卫生健康委员会医政医管局. 脑胶质瘤诊疗规范(2018年版)[J]. 中华神经外科杂志, 2019, 35(3): 217-239. DOI: 10.3760/cma.j.issn.1001-2346.2019.03.001.
|
| [4] |
陈雯琳, 王月坤, 刘千舒, 等. 2022年度我国脑胶质瘤领域研究进展[J]. 协和医学杂志, 2023, 14(5): 983-990. DOI: 10.12290/xhyxzz.2023-0321.
|
| [5] |
Huang F, Li S, Wang X, et al. Serum lipids concentration on prognosis of high-grade glioma[J]. Cancer Causes Control, 2023, 34(9): 801-811. DOI: 10.1007/s10552-023-01710-1.
|
| [6] |
Zhang D, Li H, Jia W. Exploration of the prognostic value of the resection of adult brainstem high-grade glioma based on competing risk model, propensity score matching, and conditional survival rate[J]. Neurol Sci, 2023, 44(5): 1755-1764. DOI: 10.1007/s10072-022-06557-z.
pmid: 36604383
|
| [7] |
Wu S, Wang C, Li N, et al. Analysis of prognostic factors and surgical management of elderly patients with low-grade gliomas[J]. World Neurosurg, 2023, 176: e20-e31. DOI: 10.1016/j.wneu.2023.02.099.
|
| [8] |
Lin Y, Li H, Ge Q, et al. Establishment and validation of a prognostic prediction model for glioma based on key genes and clinical factors[J]. Transl Cancer Res, 2025, 14(1): 240-253. DOI: 10.21037/tcr-24-1035.
pmid: 39974385
|
| [9] |
Hanif S, Yousaf I, Iqbal M, et al. Brain herniation and subsequent complications following partial resection of high-grade glioma: a case report[J]. Clin Case Rep, 2024, 12(1): e8407. DOI: 10.1002/ccr3.8407.
|
| [10] |
Lipková J, Menze B, Wiestler B, et al. Modelling glioma progression, mass effect and intracranial pressure in patient anatomy[J]. J R Soc Interface, 2022, 19(188): 20210922. DOI: 10.1098/rsif.2021.0922.
|
| [11] |
Pasqualetti F, Lombardi G, Gadducci G, et al. Brain stem glioma recurrence: exploring the therapeutic frontiers[J]. J Pers Med, 2024, 14(9): 899. DOI: 10.3390/jpm14090899.
|
| [12] |
Fuster-Garcia E, Thokle Hovden I, Fløgstad Svensson S, et al. Quantification of tissue compression identifies high-grade glioma patients with reduced survival[J]. Cancers (Basel), 2022, 14(7): 1725. DOI: 10.3390/cancers14071725.
|
| [13] |
Gunawan PY, Islam AA, July J, et al. Karnofsky performance scale and neurological assessment of neuro-oncology scale as early predictor in glioma[J]. Asian Pac J Cancer Prev, 2020, 21(11): 3387-3392. DOI: 10.31557/APJCP.2020.21.11.3387.
|
| [14] |
Hei B, Ouyang J, Gao Q, et al. Analysis of changes in KPS scores and imaging signs in deep brain gliomas by DWI combined with intraoperative ultrasound resection[J]. Altern Ther Health Med, 2024, 30(5): 110-117. DOI: 10.23736/S0390-5616.19.04735-0.
|
| [15] |
Shin I, Sim Y, Choi SH, et al. Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas[J]. J Neurooncol, 2024, 168(2): 239-247. DOI: 10.1007/s11060-024-04656-9.
|
| [16] |
Kivioja T, Posti JP, Sipilä J, et al. Motor dysfunction as a primary symptom predicts poor outcome: multicenter study of glioma symptoms[J]. Front Oncol, 2023, 13: 1305725. DOI: 10.3389/fonc.2023.1305725.
|
| [17] |
Decavèle M, Gatulle N, Weiss N, et al. One-year survival of patients with high-grade glioma discharged alive from the intensive care unit[J]. J Neurol, 2021, 268(2): 516-525. DOI: 10.1007/s00415-020-10191-0.
|
| [18] |
Wan Y, Li G, Deng J, et al. A gene signature predicting prognosis of patients with lower-grade gliomas receiving temozolomide therapy[J]. Horm Cancer, 2023, 14(1): 202. DOI: 10.1007/s12672-023-00818-9.
|
| [19] |
Yu S, Wu J, Jing Y, et al. Research trends in glioma chemoradiotherapy resistance: a bibliometric analysis (2003-2023)[J]. Front Oncol, 2025, 15: 1539937. DOI: 10.3389/fonc.2025.1539937.
|
| [20] |
Wetzel EA, Nohman AI, Hsieh AL, et al. A multi-center, clinical analysis of IDH-mutant gliomas, WHO grade 4: implications for prognosis and clinical trial design[J]. J Neurooncol, 2025, 171(2): 373-381. DOI: 10.1007/s11060-024-04852-7.
|
| [21] |
Zhang J, Qiu X, Feng J, et al. MGMT promoter methylation is a strong prognostic factor for survival after progression in high-grade gliomas[J]. Chin Neurosurg J, 2024, 10(1): 24. DOI: 10.1186/s41016-024-00375-2.
|
| [22] |
Singh A, Singh A, Agrawal S, et al. Prognostic significance and clinicopathological correlations of epigenetic MGMT gene silencing in high grade diffuse gliomas[J]. Discoveries (Craiova), 2023, 11(3): e175. DOI: 10.15190/d.2023.14.
|
| [23] |
朱一硕, 崔玉洁, 刘崎, 等. 脑胶质瘤患者术后早期复发危险因素分析及预测模型构建[J]. 国际肿瘤学杂志, 2022, 49(2): 79-83. DOI: 10.3760/cma.j.cn371439-20210121-00012.
|
| [24] |
Fan ZC, Zhao WJ, Jiao Y, et al. Risk factors and predictive nomogram for survival in elderly patients with brain glioma[J]. Curr Med Sci, 2024, 44(4): 759-770. DOI: 10.1007/s11596-024-2880-4.
|
| [25] |
牛弘川, 梁剑峰. 脑胶质瘤预后因素分析及其列线图预测模型的建立[J]. 中华肿瘤防治杂志, 2023, 30(3): 140-146. DOI: 10.16073/j.cnki.cjcpt.2023.03.03.
|